These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32745279)

  • 21. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
    Chin KL; Ofori-Asenso R; Si S; Hird TR; Magliano DJ; Zoungas S; Liew D
    Sci Rep; 2019 Mar; 9(1):3256. PubMed ID: 30824788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes.
    Pawaskar M; Bilir SP; Kowal S; Li Q; Weiss T; Davies G
    Am J Manag Care; 2021 Aug; 27(8):e269-e277. PubMed ID: 34460181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.
    Permsuwan U; Dilokthornsakul P; Thavorn K; Saokaew S; Chaiyakunapruk N
    J Med Econ; 2017 Feb; 20(2):171-181. PubMed ID: 27645706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
    Parizo JT; Goldhaber-Fiebert JD; Salomon JA; Khush KK; Spertus JA; Heidenreich PA; Sandhu AT
    JAMA Cardiol; 2021 Aug; 6(8):926-935. PubMed ID: 34037681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.
    Gu S; Mu Y; Zhai S; Zeng Y; Zhen X; Dong H
    PLoS One; 2016; 11(11):e0165629. PubMed ID: 27806087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
    Garnock-Jones KP
    Drugs; 2017 Mar; 77(3):319-330. PubMed ID: 28176222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
    Geng J; Yu H; Mao Y; Zhang P; Chen Y
    Pharmacoeconomics; 2015 Jun; 33(6):581-97. PubMed ID: 25736235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.
    Erhardt W; Bergenheim K; Duprat-Lomon I; McEwan P
    Clin Drug Investig; 2012 Mar; 32(3):189-202. PubMed ID: 22292415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
    Bailey CJ; Del Prato S; Wei C; Reyner D; Saraiva G
    Diabetes Obes Metab; 2019 Nov; 21(11):2564-2569. PubMed ID: 31364269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.
    Norhammar A; Bodegard J; Nyström T; Thuresson M; Rikner K; Nathanson D; Eriksson JW
    Diabetes Obes Metab; 2019 Dec; 21(12):2651-2659. PubMed ID: 31379124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom.
    Bennett H; Tank A; Evans M; Bergenheim K; McEwan P
    Diabetes Obes Metab; 2020 Jul; 22(7):1047-1055. PubMed ID: 32037675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Obes Metab; 2017 Jun; 19(6):831-841. PubMed ID: 28116795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study.
    Escobar C; Morales C; Capel M; Simón S; Pérez-Alcántara F; Pomares E
    BMC Health Serv Res; 2022 Feb; 22(1):217. PubMed ID: 35177053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis.
    Cortesi PA; Antonazzo IC; Palladino P; Gnesi M; Mele S; D'Amelio M; Zanzottera Ferrari E; Mazzaglia G; Mantovani LG
    Acta Diabetol; 2024 Aug; 61(8):1017-1028. PubMed ID: 38634912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
    Scheen AJ
    Clin Pharmacokinet; 2017 Jul; 56(7):703-718. PubMed ID: 28039605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
    Nguyen E; Coleman CI; Nair S; Weeda ER
    J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes.
    Vitale C; Rosano GM; Prasad K
    Cardiovasc Diabetol; 2016 Apr; 15():55. PubMed ID: 27039303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.